<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496183</url>
  </required_header>
  <id_info>
    <org_study_id>PCH0320106A</org_study_id>
    <nct_id>NCT01496183</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Olanzapine in Healthy Males</brief_title>
  <official_title>Metabolic Effects of Olanzapine in Healthy Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at how a two-week use of a medication called Olanzapine
      might change appetite, physical activity, resting metabolic rate, body composition, and
      weight in healthy men.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Weight</measure>
    <time_frame>Assessed at baseline and 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Composition</measure>
    <time_frame>baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
    <description>lean body mass (kg) and fat mass (kg) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-Hour Dietary Recall</measure>
    <time_frame>Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
    <description>24-hour dietary intake recall at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Resting Metabolic Rate</measure>
    <time_frame>baseline and 2weeks of treatment</time_frame>
    <description>Resting metabolic rate at baseline and after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Triglycerides</measure>
    <time_frame>Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
    <description>Triglycerides (mg/dl) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glucose</measure>
    <time_frame>Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
    <description>Glucose (mg/dl) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Leptin</measure>
    <time_frame>Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
    <description>Leptin (ng/ml) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin</measure>
    <time_frame>Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
    <description>Insulin (µIU/ml) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Total Cholesterol</measure>
    <time_frame>baseline and 2 weeks treatment</time_frame>
    <description>Total cholesterol at baseline and after 2 weeks treatment with olanzapine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL</measure>
    <time_frame>baseline and 2 weeks treatment</time_frame>
    <description>Low-density lipoprotein at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL</measure>
    <time_frame>baseline and 2 weeks treatment</time_frame>
    <description>High-density lipoprotein at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity as Measured Using a Physical Activity Monitor</measure>
    <time_frame>baseline and 2 week treatment</time_frame>
    <description>Change from baseline in physical activity. Physical activity was measured using an activity monitor that subjects wore around their waist throughout baseline and treatment days. Subjects were instructed to remove the monitor when sleeping or engaging in water-based activities, and to report on a daily log the times that they were wearing and removing the device. Physical activity was monitored during weekdays and weekend days. Physical activity data were collected in 60-second epochs. The results are reported as average counts per day of physical activity for weekdays and weekend days at baseline and 2 week treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Laboratory Breakfast Intake</measure>
    <time_frame>baseline and 2 week treatment</time_frame>
    <description>Total kcal intake at breakfast in a laboratory setting at baseline and after 2 week of treatment with olanzapine or placebo</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
    <arm_group_label>Olanzapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule administered orally at bedtime for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Volunteer

          -  Male

          -  Aged 18-35 years

          -  Body Mass Index (BMI): &lt;30 kg/m2

        Exclusion Criteria:

          -  Presence of any medical disorder that may confound the assessment of relevant
             biological measures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven L Dubovsky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The State University of New York at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, The State University of New York at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 13, 2011</study_first_submitted>
  <study_first_submitted_qc>December 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <results_first_submitted>November 24, 2014</results_first_submitted>
  <results_first_submitted_qc>November 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 1, 2014</results_first_posted>
  <last_update_submitted>July 19, 2018</last_update_submitted>
  <last_update_submitted_qc>July 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Steven Dubovsky</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Olanzapine</title>
          <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Olanzapine</title>
          <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" spread="2.5"/>
                    <measurement group_id="B2" value="23.1" spread="5.1"/>
                    <measurement group_id="B3" value="23.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight</title>
        <time_frame>Assessed at baseline and 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days Six subjects from the placebo group completed the 2-week double-blind trial and were included in the analysis.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.5"/>
                    <measurement group_id="O2" value="1.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Composition</title>
        <description>lean body mass (kg) and fat mass (kg) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
        <time_frame>baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
        <population>The Body Composition assessment was not implemented at the start of the study but once the study already started. Therefore, not all study participants who completed the study got the Body Composition assessment done. Only 3 participants in the Placebo Group and 6 participants in the Olanzapine Group got the Body Composition assessment done.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Composition</title>
          <description>lean body mass (kg) and fat mass (kg) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
          <population>The Body Composition assessment was not implemented at the start of the study but once the study already started. Therefore, not all study participants who completed the study got the Body Composition assessment done. Only 3 participants in the Placebo Group and 6 participants in the Olanzapine Group got the Body Composition assessment done.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>lean body mass at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" spread="0.7"/>
                    <measurement group_id="O2" value="65.8" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lean body mass at 2 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" spread="1.7"/>
                    <measurement group_id="O2" value="67.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fat mass at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="11.7"/>
                    <measurement group_id="O2" value="16.5" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fat mass at 2 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="10.0"/>
                    <measurement group_id="O2" value="17.4" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24-Hour Dietary Recall</title>
        <description>24-hour dietary intake recall at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
        <time_frame>Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-Hour Dietary Recall</title>
          <description>24-hour dietary intake recall at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1748" spread="567"/>
                    <measurement group_id="O2" value="2410" spread="1591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1785" spread="562"/>
                    <measurement group_id="O2" value="2374" spread="1073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Resting Metabolic Rate</title>
        <description>Resting metabolic rate at baseline and after 2 weeks of treatment</description>
        <time_frame>baseline and 2weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Resting Metabolic Rate</title>
          <description>Resting metabolic rate at baseline and after 2 weeks of treatment</description>
          <units>kcal/24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1702" spread="217"/>
                    <measurement group_id="O2" value="1855" spread="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1689" spread="309"/>
                    <measurement group_id="O2" value="1858" spread="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Triglycerides</title>
        <description>Triglycerides (mg/dl) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
        <time_frame>Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
        <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 1 participant from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Triglycerides</title>
          <description>Triglycerides (mg/dl) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
          <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 1 participant from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 12.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4" spread="13.6"/>
                    <measurement group_id="O2" value="93.0" spread="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" spread="22.1"/>
                    <measurement group_id="O2" value="136.6" spread="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glucose</title>
        <description>Glucose (mg/dl) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
        <time_frame>Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
        <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 2 participants from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 11.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucose</title>
          <description>Glucose (mg/dl) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
          <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 2 participants from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 11.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" spread="7.4"/>
                    <measurement group_id="O2" value="78.6" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="4.2"/>
                    <measurement group_id="O2" value="82.2" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Leptin</title>
        <description>Leptin (ng/ml) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
        <time_frame>Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
        <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 2 participants from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 11.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Leptin</title>
          <description>Leptin (ng/ml) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
          <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 2 participants from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 11.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="3.3"/>
                    <measurement group_id="O2" value="3.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.0"/>
                    <measurement group_id="O2" value="5.7" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin</title>
        <description>Insulin (µIU/ml) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
        <time_frame>Assessed at different time points: baseline and 2 weeks of treatment (olanzapine or placebo)</time_frame>
        <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 2 participants from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 11.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin</title>
          <description>Insulin (µIU/ml) at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
          <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 2 participants from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 11.</population>
          <units>µIU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="3.5"/>
                    <measurement group_id="O2" value="6.2" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="2.7"/>
                    <measurement group_id="O2" value="10.1" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Total Cholesterol</title>
        <description>Total cholesterol at baseline and after 2 weeks treatment with olanzapine or placebo</description>
        <time_frame>baseline and 2 weeks treatment</time_frame>
        <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 1 participant from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Total Cholesterol</title>
          <description>Total cholesterol at baseline and after 2 weeks treatment with olanzapine or placebo</description>
          <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 1 participant from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 12.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.2" spread="23.7"/>
                    <measurement group_id="O2" value="156.8" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.4" spread="21.1"/>
                    <measurement group_id="O2" value="167.0" spread="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL</title>
        <description>Low-density lipoprotein at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
        <time_frame>baseline and 2 weeks treatment</time_frame>
        <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 1 participant from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>LDL</title>
          <description>Low-density lipoprotein at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
          <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 1 participant from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 12.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.8" spread="25.2"/>
                    <measurement group_id="O2" value="86.9" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0" spread="12.5"/>
                    <measurement group_id="O2" value="93.7" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL</title>
        <description>High-density lipoprotein at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
        <time_frame>baseline and 2 weeks treatment</time_frame>
        <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 1 participant from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>HDL</title>
          <description>High-density lipoprotein at baseline and after 2 weeks of treatment with olanzapine or placebo</description>
          <population>Note regarding the difference between the Overall Number of Participants Analyzed and the Participant Flow: Blood sample could not be collected from 1 participant from the Placebo Group and 1 participant from the Olanzapine Group. Therefore, the number of participants analyzed for the Placebo Group is 5 and for the Olanzapine Group is 12.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6" spread="10.2"/>
                    <measurement group_id="O2" value="51.3" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" spread="6.8"/>
                    <measurement group_id="O2" value="46.1" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Activity as Measured Using a Physical Activity Monitor</title>
        <description>Change from baseline in physical activity. Physical activity was measured using an activity monitor that subjects wore around their waist throughout baseline and treatment days. Subjects were instructed to remove the monitor when sleeping or engaging in water-based activities, and to report on a daily log the times that they were wearing and removing the device. Physical activity was monitored during weekdays and weekend days. Physical activity data were collected in 60-second epochs. The results are reported as average counts per day of physical activity for weekdays and weekend days at baseline and 2 week treatment.</description>
        <time_frame>baseline and 2 week treatment</time_frame>
        <population>Due to poor participant's compliance with the study requirements for physical activity data collection, the data from 4 participants from the olanzapine group could not be used for analysis purpose.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Activity as Measured Using a Physical Activity Monitor</title>
          <description>Change from baseline in physical activity. Physical activity was measured using an activity monitor that subjects wore around their waist throughout baseline and treatment days. Subjects were instructed to remove the monitor when sleeping or engaging in water-based activities, and to report on a daily log the times that they were wearing and removing the device. Physical activity was monitored during weekdays and weekend days. Physical activity data were collected in 60-second epochs. The results are reported as average counts per day of physical activity for weekdays and weekend days at baseline and 2 week treatment.</description>
          <population>Due to poor participant's compliance with the study requirements for physical activity data collection, the data from 4 participants from the olanzapine group could not be used for analysis purpose.</population>
          <units>counts per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline - weekdays</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410,029" spread="200,091"/>
                    <measurement group_id="O2" value="263,720" spread="131,638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 week treatment - weekdays</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279,722" spread="119,879"/>
                    <measurement group_id="O2" value="263,757" spread="115,456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline - weekend days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279,149" spread="106,671"/>
                    <measurement group_id="O2" value="277,298" spread="162,147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 week treatment - weekend days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247,036" spread="136,553"/>
                    <measurement group_id="O2" value="198,382" spread="117,252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Laboratory Breakfast Intake</title>
        <description>Total kcal intake at breakfast in a laboratory setting at baseline and after 2 week of treatment with olanzapine or placebo</description>
        <time_frame>baseline and 2 week treatment</time_frame>
        <population>The Laboratory Breakfast Intake assessment was not performed at the start of the study but was initiated during the course of the study. Only 3 participants from the Placebo group and 6 participants from the Olanzapine group completed the Laboratory Breakfast Intake assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Breakfast Intake</title>
          <description>Total kcal intake at breakfast in a laboratory setting at baseline and after 2 week of treatment with olanzapine or placebo</description>
          <population>The Laboratory Breakfast Intake assessment was not performed at the start of the study but was initiated during the course of the study. Only 3 participants from the Placebo group and 6 participants from the Olanzapine group completed the Laboratory Breakfast Intake assessment.</population>
          <units>kcal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1396" spread="160"/>
                    <measurement group_id="O2" value="864" spread="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 week treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1567" spread="478"/>
                    <measurement group_id="O2" value="1058" spread="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: Placebo capsule administered orally at bedtime for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Olanzapine</title>
          <description>Olanzapine: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The small sample size, the exclusion of obese subjects, and the short olanzapine exposure in the current study may limit the interpretation and generalizability of our findings.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Elsa Daurignac, Research Assistant Professor</name_or_title>
      <organization>The State University of New York at Buffalo</organization>
      <phone>716-898-4540</phone>
      <email>ecd3@buffalo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

